Nanotechnology: Future of Oncotherapy

被引：67
|
作者：
Gharpure, Kshipra M. [1 ]
Wu, Sherry Y. [1 ]
Li, Chun [2 ]
Lopez-Berestein, Gabriel [3 ,4 ]
Sood, Anil K. [1 ,2 ,4 ,5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Expt Therapeut, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 14期
关键词：
PEGYLATED LIPOSOMAL DOXORUBICIN; METASTATIC BREAST-CANCER; ADVANCED SOLID TUMORS; IRON-OXIDE NANOPARTICLES; HOLLOW GOLD NANOSPHERES; LYMPH-NODE METASTASES; PHASE-III TRIAL; DRUG-DELIVERY; IN-VIVO; CONVENTIONAL DOXORUBICIN;
D O I：
10.1158/1078-0432.CCR-14-1189
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent advances in nanotechnology have established its importance in several areas including medicine. The myriad of applications in oncology range from detection and diagnosis to drug delivery and treatment. Although nanotechnology has attracted a lot of attention, the practical application of nanotechnology to clinical cancer care is still in its infancy. This review summarizes the role that nanotechnology has played in improving cancer therapy, its potential for affecting all aspects of cancer care, and the challenges that must be overcome to realize its full promise. (C) 2015 AACR.
引用
收藏
页码：3121 / 3130
页数：10
相关论文
共 50 条
12345